Novartis 3Q

3Q Revenues: $11.1 billion (+3%)

3Q Earnings: $2.1 billion (+1%)

YTD Revenues: $31.3 billion (flat)

YTD Earnings: $6.1 billion (-8%)

Comments: Pharmaceutical sales in the quarter were $7.2 billion (+8%). Diovan sales were $4.4 billion (+5% in local currencies), driven by expansion in Japan, which accounts for approximately 20% of sales. Exforge sales were $475 million (+81% lc). Tekturna/Rasilez sales were $202 million (+114% lc). Gleevec/Glivec sales were $2.9 billion (+12% lc). Zometa sales were $1.1 billion(+9% lc). Femara sales were $925 million (+16% lc). Exjade sales were $469 million (+30% lc). Sandoz revenue was $1.9 billion (-3%). Vaccines and Diagnostics sales were down 18% to $543 million, due to lower sales of H5N1 (avian flu) pandemic vaccines in 2009.